2.40
-2.04%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enzymatica AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker ENZY.ST. It has been listed since 14 June 2011. In the fiscal year to 31 December 2025, it reported revenue of SEK 53.9m and a net loss of SEK 51.9m. At that date it held total assets of SEK 142.0m and shareholders' equity of SEK 124.2m.
Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Jun 2011
- Employees
- 17
- Website
- enzymatica.se ↗
Leadership
Pay as last reported
- Mr. Bengt BaronIndependent Chairman of the Board, since 2016SEK 500,000
- Mr. Claus EgstrandChief Executive OfficerSEK 5.4m
- Ms. Therese FilmerssonDeputy Chief Executive Officer, Chief Financial OfficerSEK 1.3m
- Mr. Claes MolinGeneral Manager - Iceland
- Ms. Anna SoederlundDirector of Sales and Marketing
- Ms. Charlotte AnderssonDirector Quality AssuranceSEK 225,000
- Mr. Chris CzyrkoCommercial Director
- Ms. Charlotte Hodgkins-ByrneDirector of Strategic Partnerships
- Ms. Ann Christine ProvoostDirector of Regulatory and Clinical Affairs
- Mr. Mats AnderssonDirectorSEK 225,000
- Ms. Moa FranssonIndependent DirectorSEK 225,000
- Ms. Louise NicolinIndependent DirectorSEK 275,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 45
- Social
- 51
- Governance
- 31
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enzymatica AB (publ) has several strengths that contribute to its success in the market. Firstly, the company has a strong portfolio of innovative and highly effective enzyme-based products, which have gained a strong reputation among its customers. These products provide various health benefits and cater to different needs, such as immune system support and oral care.
- Another strength of Enzymatica is its strong research and development capabilities. The company invests heavily in R&D to constantly improve and expand its product offerings, ensuring they remain at the forefront of the industry. This commitment to innovation allows Enzymatica to stay ahead of competitors and meet the evolving needs of customers.
- Furthermore, Enzymatica has established strong distribution channels, both domestically and internationally. The company has partnerships with reputable retailers and distributors, allowing its products to reach a wide customer base. This extensive distribution network provides Enzymatica with a competitive advantage and helps in expanding its market presence.
Weaknesses
- Despite its strengths, Enzymatica also faces certain weaknesses that could hinder its growth. One of these weaknesses is the company's heavy reliance on a limited number of product lines. While these products have been successful, they present a risk if they were to face unexpected challenges or decline in popularity. Enzymatica should focus on diversifying its product portfolio to minimize this risk.
- Additionally, Enzymatica's geographic presence is currently concentrated in a few key markets. This geographic concentration exposes the company to greater risks from market-specific factors, such as regulatory changes or economic downturns. Expanding into new markets would help Enzymatica reduce its dependence on any single market and enhance its overall resilience.
Opportunities
- Enzymatica has several opportunities to capitalize on. Firstly, there is a growing global demand for natural and preventive healthcare products. This trend aligns with Enzymatica's focus on enzyme-based products, providing the company with a significant opportunity to expand its customer base and gain market share.
- Moreover, Enzymatica can leverage its strong R&D capabilities to develop new products that target emerging health concerns. By identifying and addressing unmet customer needs, the company can stay ahead of the competition and establish itself as a leader in the industry.
- Additionally, Enzymatica can explore strategic partnerships or collaborations with complementary companies in the healthcare or consumer goods sectors. Such alliances can open doors to new distribution channels, enhance brand visibility, and strengthen market positioning.
Threats
- Enzymatica faces a number of threats that could affect its operations and market position. One of the major threats is intense competition from both established players and emerging companies in the healthcare industry. To mitigate this threat, Enzymatica needs to continuously invest in innovation, maintain product quality, and effectively market its unique selling propositions.
- Moreover, regulatory changes and requirements could pose challenges for Enzymatica. Compliance with evolving regulations, especially related to product claims and safety, is crucial to avoid disruptions in business operations and maintain consumer trust.
- Furthermore, economic downturns or fluctuations in exchange rates could impact Enzymatica's financial performance. With a diversified geographical presence and an agile business strategy, the company should be prepared to navigate such challenges effectively.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.